Alendronate and Parathyroid Hormone
To the Editor: Black et al. 1 and Cosman et al. 2 (Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpr...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2005-12, Vol.353 (24), p.2618-2619 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2619 |
|---|---|
| container_issue | 24 |
| container_start_page | 2618 |
| container_title | The New England journal of medicine |
| container_volume | 353 |
| creator | Muldowney, Francis P |
| description | To the Editor:
Black et al.
1
and Cosman et al.
2
(Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpretation of the results.
In a study of elderly subjects in Ireland with vitamin D deficiency, my colleagues and I observed a surprisingly larger number who had low serum levels of 25-hydroxyvitamin D as well as mildly abnormal calcium, phosphorus, and alkaline phosphatase levels.
3
,
4
Cosman and colleagues found a similar pattern of low serum levels . . . |
| doi_str_mv | 10.1056/NEJMc055376 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68895584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68895584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-cdfae30cb760ed8e1eedb5fb584f264def2cef55290dafa94171c8d4d30dea953</originalsourceid><addsrcrecordid>eNpt0DtPwzAUhmELgWgpTOyoUiUWFLDjS-KxqgoFlcsAs-XYxyJVHBc7HfrvCWokGDjLWR69w4fQJcG3BHNx97J8ejaYc1qIIzQmnNKMMSyO0RjjvMxYIekInaW0wf0RJk_RiAjKmcT5GM3mDbQ2hlZ3MNWtnb7pqLvPfQy1na5C9KGFc3TidJPgYvgT9HG_fF-ssvXrw-Nivs4MJXmXGes0UGyqQmCwJRAAW3FX8ZK5XDALLjfgOM8lttppyUhBTGmZpdiClpxO0PWhu43hawepU75OBppGtxB2SYmylLyv9fDmAE0MKUVwahtrr-NeEax-NlF_Nun11ZDdVR7srx1G6MHsALxPqoWN_zfzDW5NZtU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68895584</pqid></control><display><type>article</type><title>Alendronate and Parathyroid Hormone</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine Current</source><creator>Muldowney, Francis P</creator><creatorcontrib>Muldowney, Francis P</creatorcontrib><description>To the Editor:
Black et al.
1
and Cosman et al.
2
(Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpretation of the results.
In a study of elderly subjects in Ireland with vitamin D deficiency, my colleagues and I observed a surprisingly larger number who had low serum levels of 25-hydroxyvitamin D as well as mildly abnormal calcium, phosphorus, and alkaline phosphatase levels.
3
,
4
Cosman and colleagues found a similar pattern of low serum levels . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc055376</identifier><identifier>PMID: 16354902</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Alendronate - therapeutic use ; Bone Remodeling ; Drug Therapy, Combination ; Female ; Humans ; Osteoporosis, Postmenopausal - complications ; Osteoporosis, Postmenopausal - drug therapy ; Parathyroid Hormone - therapeutic use ; Vitamin D - analogs & derivatives ; Vitamin D - blood ; Vitamin D - therapeutic use ; Vitamin D Deficiency - complications ; Vitamin D Deficiency - drug therapy</subject><ispartof>The New England journal of medicine, 2005-12, Vol.353 (24), p.2618-2619</ispartof><rights>Copyright © 2005 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c312t-cdfae30cb760ed8e1eedb5fb584f264def2cef55290dafa94171c8d4d30dea953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc055376$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc055376$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16354902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muldowney, Francis P</creatorcontrib><title>Alendronate and Parathyroid Hormone</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Black et al.
1
and Cosman et al.
2
(Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpretation of the results.
In a study of elderly subjects in Ireland with vitamin D deficiency, my colleagues and I observed a surprisingly larger number who had low serum levels of 25-hydroxyvitamin D as well as mildly abnormal calcium, phosphorus, and alkaline phosphatase levels.
3
,
4
Cosman and colleagues found a similar pattern of low serum levels . . .</description><subject>Alendronate - therapeutic use</subject><subject>Bone Remodeling</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Osteoporosis, Postmenopausal - complications</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Parathyroid Hormone - therapeutic use</subject><subject>Vitamin D - analogs & derivatives</subject><subject>Vitamin D - blood</subject><subject>Vitamin D - therapeutic use</subject><subject>Vitamin D Deficiency - complications</subject><subject>Vitamin D Deficiency - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0DtPwzAUhmELgWgpTOyoUiUWFLDjS-KxqgoFlcsAs-XYxyJVHBc7HfrvCWokGDjLWR69w4fQJcG3BHNx97J8ejaYc1qIIzQmnNKMMSyO0RjjvMxYIekInaW0wf0RJk_RiAjKmcT5GM3mDbQ2hlZ3MNWtnb7pqLvPfQy1na5C9KGFc3TidJPgYvgT9HG_fF-ssvXrw-Nivs4MJXmXGes0UGyqQmCwJRAAW3FX8ZK5XDALLjfgOM8lttppyUhBTGmZpdiClpxO0PWhu43hawepU75OBppGtxB2SYmylLyv9fDmAE0MKUVwahtrr-NeEax-NlF_Nun11ZDdVR7srx1G6MHsALxPqoWN_zfzDW5NZtU</recordid><startdate>20051215</startdate><enddate>20051215</enddate><creator>Muldowney, Francis P</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051215</creationdate><title>Alendronate and Parathyroid Hormone</title><author>Muldowney, Francis P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-cdfae30cb760ed8e1eedb5fb584f264def2cef55290dafa94171c8d4d30dea953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Alendronate - therapeutic use</topic><topic>Bone Remodeling</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Osteoporosis, Postmenopausal - complications</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Parathyroid Hormone - therapeutic use</topic><topic>Vitamin D - analogs & derivatives</topic><topic>Vitamin D - blood</topic><topic>Vitamin D - therapeutic use</topic><topic>Vitamin D Deficiency - complications</topic><topic>Vitamin D Deficiency - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muldowney, Francis P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muldowney, Francis P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alendronate and Parathyroid Hormone</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2005-12-15</date><risdate>2005</risdate><volume>353</volume><issue>24</issue><spage>2618</spage><epage>2619</epage><pages>2618-2619</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Black et al.
1
and Cosman et al.
2
(Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpretation of the results.
In a study of elderly subjects in Ireland with vitamin D deficiency, my colleagues and I observed a surprisingly larger number who had low serum levels of 25-hydroxyvitamin D as well as mildly abnormal calcium, phosphorus, and alkaline phosphatase levels.
3
,
4
Cosman and colleagues found a similar pattern of low serum levels . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16354902</pmid><doi>10.1056/NEJMc055376</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2005-12, Vol.353 (24), p.2618-2619 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68895584 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine Current |
| subjects | Alendronate - therapeutic use Bone Remodeling Drug Therapy, Combination Female Humans Osteoporosis, Postmenopausal - complications Osteoporosis, Postmenopausal - drug therapy Parathyroid Hormone - therapeutic use Vitamin D - analogs & derivatives Vitamin D - blood Vitamin D - therapeutic use Vitamin D Deficiency - complications Vitamin D Deficiency - drug therapy |
| title | Alendronate and Parathyroid Hormone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T04%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alendronate%20and%20Parathyroid%20Hormone&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Muldowney,%20Francis%20P&rft.date=2005-12-15&rft.volume=353&rft.issue=24&rft.spage=2618&rft.epage=2619&rft.pages=2618-2619&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc055376&rft_dat=%3Cproquest_cross%3E68895584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68895584&rft_id=info:pmid/16354902&rfr_iscdi=true |